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Abstract
Background: Cats with chronic kidney disease (CKD) have an increased prevalence
of positive urine cultures (PUC). Limited information is available regarding the prog-
nosis of cats with CKD and concurrent PUC.
Objective: To determine the association of PUC with survival time and disease pro-
gression in cats with CKD.
Animals: Medical records of 509 cats diagnosed with azotemic CKD between 1997
and 2018.
Methods: Cats were classified as having “no-PUC” or “PUC.” The PUC cats were fur-
ther classified as having 1 or multiple PUC, and also were classified based on the
presence or absence of clinical signs of urinary tract infection (UTI). Progression of
CKD was defined as a plasma creatinine concentration increase of ≥25% within
365 days of CKD diagnosis; PUC also must have occurred within this time frame.
Survival time and frequency of CKD progression were compared between groups.
Results: No significant difference in survival time was found between cats with no-
PUC and cats with any number of PUC (P = .91), or between cats with no-PUC, 1
PUC or multiple PUC (P = .37). Also, no significant difference was found in the fre-
quency of CKD progression between PUC and no-PUC cats (P = .5), or among no-
PUC, 1 PUC and multiple PUC cats (P = .22). When assessing cats with clinical signs
of lower UTI, no significant difference was found in the frequency of CKD progres-
sion between cats with true UTI, subclinical bacteriuria or no-PUC (P = .8).
Conclusions and Clinical Importance: When treated with antibiotics, PUC in cats
with CKD do not affect disease progression or survival time.
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1 | INTRODUCTION
The prevalence of bacteriuria in cats generally is considered to be
low.1 In 1 study that assessed cats of all ages, <4% of cats that pres-
ented with clinical signs of lower urinary tract disease had positive
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urine cultures (PUC).2 In contrast, cats with chronic kidney disease
(CKD) historically have a considerably higher prevalence of PUC,
reported as 22% in 1 study.3 A potential contributor to the increased
prevalence of bacteriuria in cats with CKD is the lack of urine hyper-
tonicity in these patients, which acts as a host defense mechanism of
the lower urinary tract.4 The majority of cats with CKD and PUC show
no overt clinical signs of urinary tract infection (UTI) according to their
owners, raising the question of whether these cats have a true UTI or
subclinical bacteriuria, which is defined as the presence of a PUC in
the absence of clinical signs.5 One study examining urine cultures in
cats with CKD found that 18/25 cats with PUC showed no clinical
signs of UTI.6 However, previous research has found that owners
underestimate the frequency of urination in their cats, and the preva-
lence of true UTI therefore could be underestimated.7
To date, limited information is available regarding the prognosis
of patients with CKD and concurrent UTI or subclinical bacteriuria,
either in the human or veterinary medical literature. In people with
autosomal dominant polycystic kidney disease (ADPKD), UTI is
reported as a risk factor for deteriorating renal function.8 How-
ever, these cases are complicated by the presence of renal cysts,
which could predispose to upper urinary tract infection.9 In a study
of 86 cats with CKD, the presence of a PUC (subsequently treated
with antibiotics) did not affect survival.6
Various clinicopathological markers have been associated with
decreased survival time and disease progression in cats with CKD.
Proteinuria, anemia and hyperphosphatemia are associated both
with decreased survival time and progression of disease in these
patients.10-13 An understanding of such factors is important in the
appropriate management of cats with CKD, and to provide accurate
prognostic information to their owners. Because PUC is commonly
encountered in cats with CKD, and with the potential for ascending
infection and acute-on-chronic kidney injury in patients with under-
lying renal disease, understanding the role of PUC in the progression
of CKD may help improve the management of these patients. To our
knowledge, no veterinary studies have investigated the effect of
bacteriuria on the rate of disease progression in CKD. Our aims were
2-fold: to determine the association of PUC with survival time in cats
with CKD in a population of cats undergoing standardized monitor-
ing, and to determine the association of PUC with progression
of CKD.
2 | MATERIALS AND METHODS
2.1 | Case selection
Cats with azotemic CKD were retrospectively identified from a longitu-
dinal geriatric monitoring program undertaken at 2 clinics in London
(Beaumont Sainsbury Animal Hospital in Camden and People's Dispen-
sary for Sick Animals in Bow) by searching electronic medical records
between February 1997 and April 2018. All cats were ≥9 years old,
client-owned and visited these clinics for general health screening and
subsequent standardized longitudinal monitoring of their CKD.
As part of the longitudinal monitoring program, routine collection
and storage of blood and urine samples were performed with informed
owner consent, and the study protocols underwent ethical review. Cats
were determined to have azotemic CKD on the basis of plasma creatinine
concentration ≥2 mg/dL (>177 μmol/L; reference interval, 20-177 μmol/
L) with concurrent USG <1.035, or plasma creatinine concentration
≥2 mg/dL on 2 consecutive occasions 2 to 4 weeks apart. Cats diagnosed
with CKD were offered a prescription renal diet (Royal Canin Renal feline
wet and/or dry food, depending on individual cat preferences) and were
reexamined 4 to 6 weeks later. Thereafter, cats were reexamined at
8-week intervals. Cats were provided with this standard of care free of
charge until death or euthanasia or until the client declined continuation
in the study.
At each examination visit, the following data was collected: medi-
cal history, physical examination findings, and systolic blood pressure
measurement using Doppler technique as previously described.14 His-
tory information was collected using a standardized form and informa-
tion relating to thirst and urination was routinely collected. After
stabilization on the renal diet, blood and urine testing were performed
at every other reexamination appointment unless concern for lower
urinary tract signs or clinical deterioration prompted earlier reassessment.
Blood was obtained by jugular venipuncture and routine blood tests
included packed cell volume (PCV), total solids and a biochemistry profile
performed on heparinized plasma at an external commercial laboratory
(IDEXX, Wetherby, UK). Urine was obtained by cystocentesis in all cats
for which a urinary bladder was palpable, and complete urinalysis includ-
ing pH using a pH meter (Hanna HI-9124), urine specific gravity (USG),
reagent strip analysis (Combur 9 Test, Roche), and sediment examination
was performed. Collection of urine was independent of the presence of
lower urinary tract signs. Urine culture and sensitivity were performed
when urine sediment examination showed evidence of bacteriuria, hema-
turia, pyuria, or some combination of these, or in cats showing clinical
signs of UTI (eg, dysuria, hematuria).
Cats were excluded from the study if they had a concurrent diag-
nosis of hyperthyroidism or diabetes mellitus. A diagnosis of diabetes
mellitus was made on the basis of clinical findings including persistent
hyperglycemia and glucosuria. Cats were tested for hyperthyroidism
by measurement of serum total thyroxine (T4) concentrations if they
had clinical signs suggestive of hyperthyroidism (substantial weight
loss, tachycardia, palpable goiter, or some combination of these). Cats
were diagnosed as hyperthyroid if their serum total T4 concentration
was ≥55 nmol/L (reference interval 10-55 nmol/L). Cats with high-
normal serum total T4 concentration (40-55 nmol/L) were tested
again in 4 to 8 weeks. If the serum total T4 concentration remained in
the high-normal range and the cat showed clinical signs of hyperthy-
roidism, further testing for hyperthyroidism was performed (either
measurement of serum free T4 or thyroid-stimulating hormone [TSH]
concentration according to the clinical practice at the time and at the
discretion of the attending clinician). Cats also were excluded if they
never had a urine sample collected at or after the time of CKD
diagnosis, or if they were diagnosed with CKD at their last clinic
visit and thus did not have any data collected after the diagnosis
of CKD.
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2.2 | Identification, classification and management
of cats with positive urine cultures, subclinical
bacteriuria, and urinary tract infections
For the purposes of our study, cats initially were classified on the basis of
longitudinal review of clinical data as either having a PUC or not (“no-
PUC”). This classification was performed regardless of the presence or
absence of clinical signs of UTI. Historically (February 1997-June 2015)
whenever a PUC was obtained, cats routinely received a 3-week course
of PO antibiotics regardless of the presence or absence of lower urinary
tract clinical signs; the first choice was amoxicillin/clavulanic acid or cepha-
lexin PO q12h on the basis of urine culture and sensitivity results.
Fluoroquinolones were given if the isolated bacterium was resistant to
both of these first-line antibiotics. Cats with a PUC identified after June
2015 routinely received a 10-day course of antibiotics with the same anti-
microbial choices. One cat with a PUC documented after June 2015
received a 3-day course of amoxicillin/clavulanic acid (rather than a
10-day course) as part of an unrelated clinical trial. Owners were offered
reexamination of their cats 1 to 2 weeks after initiation of antibiotic treat-
ment for repeat urinalysis. Assuming the sediment examination indicated
no further evidence of bacteriuria, the antimicrobial course was completed
and cats reexamined 1 to 2 weeks after completion of the course for
another urinalysis. If on the first reexamination, the urinalysis still showed
pyuria, hematuria, bacteriuria, or some combination of these, an additional
urine culture was performed, and if the culture remained positive, the anti-
biotic course was extended to 6 weeks. The type of antibiotic was chan-
ged only if sensitivity testing indicated the organism had become resistant
to the original antibiotic, not based on lack of response. After a change of
antibiotic, the treatment duration was the same as the first course of
treatment.
The cats in the PUC group then were further classified as having
“1 PUC” or “multiple PUC” (>1 PUC) after CKD diagnosis. Cats were
classified as having multiple PUC if they had documented negative
urine cultures between positive cultures, or had different organisms
cultured on sequential urine samples. Cats with persistently positive
urine cultures despite antimicrobial treatment, and in which negative
cultures never were obtained were classified as having 1 PUC, pro-
vided the same organism was cultured each time.
For all cats at all time points when a PUC was identified, the clini-
cal records were reviewed to establish the presence or absence of
reported lower urinary tract signs including pollakiuria, hematuria,
stranguria, and dysuria. Those episodes of PUC with clinical signs
referable to the lower urinary tract were defined as “true UTI”
whereas those without such signs were considered to represent “sub-
clinical bacteriuria.” If no information was provided in the clinical
records in relation to urinary tract signs, it was assumed that the cat
had no clinical signs and was therefore subclinical.
2.3 | Survival and disease progression data
Survival in days was calculated from the date of CKD diagnosis until
the date of euthanasia, death or the study end point (30th April
2018). The date of death was recorded in the cats' medical records,
however if a cat died at home and the exact date of death was not
recalled by the owner, it was assumed that the cat died on the 15th of
the month of death. Cats that were lost to follow-up or alive at the
end of the study were censored.
Progression of CKD was defined as an increase in plasma creati-
nine concentration ≥25% within a 12-month period using the first
measurement of plasma creatinine concentration from the date of
CKD diagnosis as baseline.13 Where data were available, cats were
classified as having either progressed or not progressed within 365 days
after the diagnosis of azotemic CKD. Cats that died earlier than 365 days
after the diagnosis of CKD without documented evidence of progression
were excluded from the analysis. For PUC cats to be included in the pro-
gression analysis, the first documented PUC had to occur within 365 days
after the diagnosis of CKD.
2.4 | Statistical analysis
Statistical analyses were performed using computerized statistical
software (IBM SPSS Statistics for Windows). A P value <.05 was con-
sidered significant. Data are reported as median (25th percentile, 75th
percentile), unless otherwise is stated. Clinical variables were com-
pared using the Mann-Whitney U test or Kruskal-Wallis test for con-
tinuous data and chi-squared test for categorical data as appropriate.
Where significant differences were detected when >2 groups were
compared, Dunn's test was utilized for post hoc analysis. Survival ana-
lyses were performed using the Kaplan-Meier estimator and log rank
test, and explored in the following groups: cats with and without PUC,
cats with no-PUC, 1 PUC and multiple PUC, and number of PUC. Sur-
vival analyses also were performed using Cox proportional hazards
analysis. Progression and survival analyses were performed both with
and without cats with a single persistent PUC where documentation
of resolution was not identified.
3 | RESULTS
An electronic patient database search identified 948 cats diagnosed
with CKD between February 1997 and April 2018. However, 439 cats
were subsequently excluded leaving 509 cats for the analysis. Rea-
sons for exclusion included: only 1 clinic visit or diagnosis of CKD at
the last clinic visit (87 cats); concurrent diagnosis of hyperthyroidism
(334 cats); no urine sample collected at or after the diagnosis of CKD
(15 cats); diagnostic criteria for CKD not fulfilled when individually
assessed (3 cats). Of the 509 cats identified for analysis, 417 cats
were in the no-PUC group and 92 cats were in the PUC group. Clinical
data for cats at the time of diagnosis of CKD both with and without
PUC are presented in Table 1.
There were significantly more visits (P < .001) and numbers of
urine samples collected (P < .001) in the PUC group compared to the
no-PUC group. Positive urine cultures were observed more frequently
in female cats compared to males (P < .001). No significant differences
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were found in the following variables between the 2 groups at the
time of CKD diagnosis: age (P = .35), plasma creatinine concentration
(P = .95), PCV (P = .79), mean systolic blood pressure (P = .76), and
plasma phosphorus concentration (P = .48). No significant differences
in clinical variables were identified among the no-PUC, 1 PUC and
multiple PUC groups: age (P = .60), plasma creatinine concentration
(P = .86), PCV (P = .58), mean systolic blood pressure (P = .88), and
plasma phosphorus concentration (P = .43).
3.1 | Identification and classification of cats with
positive urine cultures
From the 92 cats in the PUC group, there were 159 episodes of PUC of
which 55 cats had only a single PUC episode. Within the multiple PUC
group (n = 37), 18 cats had 2 PUC, 13 cats had 3 PUC, 3 cats had 4 PUC,
1 cat had 5 PUC, and 2 cats had 6 PUC. Evaluating all positive cultures,
the most frequently isolated bacteria were Escherichia coli (120/159
[75.5%]) and Enterococcus faecalis (22/159 [13.8%]) with other organisms
including Staphylococcus spp., Klebsiella spp., and Proteus spp. identified in
a limited number of cases. In addition, 6/159 (3.8%) urine samples grew
both E. coli and E. faecalis concurrently. The most common urine sediment
findings were bacteriuria and pyuria (57/159 [35.8%]), bacteriuria alone
(45/159 [28.3%]) and bacteriuria, pyuria, and hematuria (23/159 [14.5%]).
Clinical signs consistent with lower urinary tract disease were
reported in 22 of 159 PUC (13.8%) consistent with true UTI; the
remainder was deemed subclinical. Twenty of the 92 cats (21.7%)
with PUC had documented clinical signs of UTI on at least 1 occasion.
Seven of these 20 cats (35%) each had only 1 true UTI during the
period of follow-up. The remaining 13 cats had >1 episode of PUC. Of
these 13 cats, 11 had only 1 true UTI with the other episode of PUC
being subclinical. One of the 13 cats had 2 episodes of PUC, both with
clinical signs, and 1 had 6 PUC, 2 of which were accompanied by clini-
cal signs of UTI. In 72 cats, the episodes of PUC were always subclini-
cal. Forty-eight (66.7%) of these 72 cats had just 1 episode of
subclinical bacteriuria documented during follow-up. In the 24 cats
with multiple episodes of subclinical bacteriuria, 13 had 2 episodes,
9 had 3 episodes, 1 had 4 episodes, and 1 had 6 episodes.
Out of the 22 true UTI episodes, the most frequently isolated
bacteria were E. coli (17 episodes; 77.3%) and E. faecalis (4 episodes;
18.2%). The 1 remaining true UTI episode was attributed to Staphylo-
cocci (4.5%). Of the 137 episodes of subclinical bacteriuria, the most
frequently isolated bacteria were E. coli (103 episodes; 75.2%),
E. faecalis (19 episodes; 13.9%), and Staphylococci (6 episodes; 4.4%).
TABLE 1 Clinicopathological, visit, and urine sample data for cats with and without positive urine cultures, at the time of diagnosis of
azotemic CKD
No-PUC cats All PUC cats 1 PUC cats Multiple PUC cats
n 417 92 55 37
Visits per cat 6 [3, 11] 12 [6, 17] 9 [4, 15] 15 [10, 20]
Urine samples per cat 3 [2, 6] 6 [4, 10] 5 [3, 7] 9 [6, 12]
PUC NA 1 [1, 2] 1 [1, 1] 3 [2, 3]
Age (years) at diagnosis 15.1 [12.8, 16.9] 15.3 [13.0, 17.8] 15.4 [13.1, 17.5] 15.1 [12.0, 17.9]
Sex 234 MN, 3 ME, 179 FN, 1 FE 15 MN, 76 FN, 1
FE
10 MN, 44 FN, 1 FE 5 MN, 32 FN
Plasma creatinine (μmol/L;
mg/dL)
216.20 [195.0, 251.90] 2.45
[2.21, 2.85]
217.30 [195.28,
258.68]
2.46 [2.21, 2.93]
218.10 [195.10, 268.0] 2.47
[2.21, 3.03]
214.50 [194.50,
246.55]
2.43 [2.2, 2.79]
IRIS stage 2 cats 309 (74%) 66 (72%) 38 (69%) 28 (75%)
IRIS stage 3 cats 93 (22%) 25 (27%) 17 (31%) 8 (22%)
IRIS stage 4 cats 15 (4%) 1 (1%) 0 1 (3%)
PCV (%) 34 [30, 37] 34 [29, 38] 34 [28, 38] 34 [31, 39]
Systolic blood pressure (mean)
(mm Hg)
145.6 [130.8, 164.5] 144.0 [130.2;
162.4]
145.6 [130.4, 164.6] 140.8 [129.7,
159.6]
Plasma phosphorus (mmol/L;
mg/dL)
1.38 [1.18, 1.69]
4.28 [3.66, 5.24]
1.44 [1.15, 1.87]
4.46 [3.57, 5.8]
1.33 [1.1, 1.73]
4.12 [3.41, 5.36]
1.52 [1.17; 2.02]
4.71 [3.63, 6.26]
Survival (days) 418 [181, 813] 576 [268, 880] 381 [154, 842] 675 [458, 884]
Cats alive at study end point 48 (12%) 10 (11%) 6 (11%) 4 (11%)
Cats dead at study end point 323 (77%) 75 (81%) 45 (82%) 30 (81%)
Cats lost to follow-up at study
end point
46 (11%) 7 (8%) 4 (7%) 3 (8%)
Note: Descriptive statistics; median [25th percentile, 75th percentile].
Abbreviations: FE, female entire; FN, female neutered; IRIS, International Renal Interest Society; ME, male entire; MN, male neutered; n, number.
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3.2 | Survival of cats with and without positive
urine cultures
At the study end point (30th April 2018), 58 of 509 cats were alive and
thus were censored in the survival analysis. The median survival of cats that
were still alive at follow-up was 455 days (189, 979). Fifty-three cats were
lost to follow-up during the study period and also were censored. The log
rank test showed no significant difference in survival time between cats
with no-PUC (estimated median survival, 418 days [181, 813]) and cats
with PUC (estimated median survival, 576 days [268, 880]; P = .91). Also
no significant difference was found in survival between cats with no-PUC
(estimated median survival, 418 days [181, 813]), 1 PUC (estimated median
survival 381 days [154, 842]), or multiple PUC (estimated median survival,
675 days [458, 884]; P = .37). These data are presented in Figure 1. The
Kaplan-Meier analysis and log rank test also were performed without cats
with persistent PUC classified as having 1 PUC (n = 8). Still, no significant
difference was found in survival time when comparing the following
groups: no-PUC vs PUC (P = .98); and no-PUC vs 1 PUC vs multiple PUC
(P = .27). There was also no difference in survival when comparing cats
based on their number of PUC (P = .78) Cox proportional hazards analysis
showed that the presence of PUC had no effect on survival in this popula-
tion of cats (hazard ratio, .99; P = .91). The number of PUC (hazard ratio,
.96; P = .43) or whether the cats had 1 PUC or multiple PUC (hazard ratio,
.95; P = .55) also had no effect on survival. When entered into a multivari-
able model, only baseline plasma creatinine concentration (P < .001), PCV
(P < .001), and plasma phosphorus concentration (P = .001) were associated
with survival.
3.3 | Evaluation of progression of CKD
Progression data within the first 365 days after CKD diagnosis were
available for 253 of 509 cats: 207 from the no-PUC group and 46 from
the PUC group. One-hundred and twenty-nine cats were excluded
from the progression analysis because they died or were euthanized
before 365 days without documented evidence of CKD progression.
Eighty-three of 207 cats (40.1%) in the no-PUC group had progression
of azotemia within 365 days, and 16 of 46 cats (34.8%) in the PUC
group had progression in the same time frame. Clinical data from the
time of CKD diagnosis for cats with stable and progressive CKD
within 365 days are presented in Table 2.
Dunn's post hoc test identified a significant difference in baseline
PCV between no-PUC cats with stable CKD and no-PUC cats with
progressive CKD, with cats with progressive disease having a lower
baseline PCV (P < .001). A significant difference in plasma phosphorus
concentration also was found between these 2 groups, with no-PUC
cats with progressive disease having a higher baseline plasma phos-
phorus concentration than no-PUC cats with stable disease (P = .01).
No significant difference was found in the frequency of CKD pro-
gression between the PUC and no-PUC cats within 365 days (P = .5).
Also, no significant difference was found in the frequency of CKD
progression when comparing no-PUC cats, 1 PUC cats and multiple
PUC cats (P = .22) within the same time period. This analysis also was
repeated after excluding the cats with persistent PUC (n = 8), because
it was hypothesized that persistent PUC could have been associated
with a worse outcome than that of cats that were only transiently
bacteriuric. However, only 2/8 cats with persistent PUC were
included in the progression analysis and the results did not change
when these cats were excluded.
Progression data within 365 days was available for 14 cats with
true UTI and 32 cats with subclinical bacteriuria. Of the 14 cats with
true UTI, 5 (35.7%) progressed and 9 (64.3%) remained stable, whereas for
those with subclinical bacteriuria, 11 (34.4%) progressed and 21 (65.6%)
remained stable. No significant difference was found in the frequency of
CKD progression among cats with true UTI, subclinical bacteriuria and no-
PUC (P = .8).
4 | DISCUSSION
Several clinicopathological factors previously have been associated
with decreased survival time in cats with CKD, including proteinuria,
decreased PCV, hyperphosphatemia and increased serum creatinine
concentration.10-12 Similarly, factors including low hematocrit, increased
serum phosphorus concentration, proteinuria and increased plasma indoxyl
sulfate concentration have been associated with progression of CKD in
cats.13,15 Concern has been raised that additional factors such as the pres-
ence of PUC (either true UTI or subclinical bacteriuria) may contribute to
both CKD progression and decreased survival. This risk is linked to the
potential for ascending infection and development of pyelonephritis, pro-
moting the cycle of interstitial inflammation and fibrosis.16 In our study, the
presence or absence of PUC in azotemic cats that underwent standardized
monitoring and were treated for their PUC had no impact on survival,
which is consistent with results of a previous study.6 Similarly, the presence
or absence of PUC, single vs multiple PUC and presence of clinical vs sub-
clinical bacteriuria were not significantly associated with the progression of
CKD over a 12-month period. However, possible changes in muscle mass
F IGURE 1 Survival curves for cats that had no positive urine
cultures (PUCs), 1 positive urine culture, or multiple positive urine
cultures after the diagnosis of azotemic chronic kidney disease (CKD)
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over time were not accounted for in the progression analysis, and it is pos-
sible that decreasing muscle mass over time may have decreased plasma
creatinine concentrations and thus affected our results. Although this possi-
bility is a limitation of the progression analysis, it would be expected that
age-related cachexia and decreasing muscle mass would affect PUC and
no-PUC cats to a similar extent. Therefore, it is considered unlikely that
these results would have changed substantially if muscle mass was incorpo-
rated into the progression analysis.
A notable limitation of our study is that all cats received antimicro-
bial treatment for their PUC, regardless of the presence or absence of
clinical signs. It currently is recommended that, in the presence of clini-
cal signs referable to the lower urinary tract, a diagnosis of clinical UTI
be made and appropriate antimicrobial treatment prescribed, but that
antimicrobial treatment should be withheld from animals with subclini-
cal bacteriuria.5 Although doing so is considered best practice from the
perspective of prudent use of antimicrobials, concern remains as to the
potential risk for the progression of renal disease and therefore out-
come and survival of cats with CKD.17 Additionally, previous research
has found that owners underestimate the frequency of urination in
their cats, potentially leading to an underestimation of the prevalence
TABLE 2 Clinicopathological data for cats with and without progression of disease within 365 days
No-PUC PUC
Variable Progressed Stable Progressed Stable P
n 83 124 16 30
Visits 7 [5, 11] 14 [10, 22] 10 [8, 16] 17 [14, 20] <.001
Urine samples 4 [3, 7] 7 [5, 11] 6 [5, 11] 9 [7, 12] <.001
n PUC 1 – – 10 (1 true UTI, 9
SB)
11 (1 true UTI, 10
SB)
2 4 (4 true UTI, 4
SB)
7 (1 true UTI, 13
SB)
3 – 9 (4 true UTI, 23
SB)
4 – 2 (2 true UTI, 6 SB)
5 1 (1 true UTI, 4
SB)
–
6 1 (0 true UTI, 6
SB)
1 (2 true UTI, 4 SB)
Days to first PUC – – 17.5 [0.0, 131.3] 0.0 [0.0, 232.8] .20
Days to progression of CKD 98 [56, 196] – 112 [49, 173] –
Cats which died/were euthanized with
progression
46 (55.4%) – 8 (50%) –
Age (years) 15.1 [12.3, 16.6] 14.4 [11.5, 15.8] 14.5 [13.0, 17.8] 14.6 [11.8, 16.7] .23
Plasma creatinine (μmol/L; mg/dL) 223.0 [201.1,
259.6]
2.52 [2.27, 2.94]
210.4 [193.4,
243.9]
2.38 [2.19, 2.76]
250.0 [197.6,
300.9]
2.83 [2.23, 3.4]
216.5 [204.6,
249.2]
2.45 [2.31, 2.82]
.08
IRIS stage (at entry) 1 – – – –
2 60 (72.3%) 96 (77.4%) 8 (50%) 23 (76.7%)
3 19 (22.9%) 27 (21.8%) 8 (50%) 7 (23.3%)
4 4 (4.8%) 1 (0.8%) – –
PCV (%) 31.5 [27.8, 35.3] 35.0 [32.0, 38.0] 33.5 [27.3, 37.3] 35.0 [32.0, 38.0] <.001
Plasma phosphorus (mmol/L; mg/dL) 1.42 [1.27, 1.79]
4.4 [3.94, 5.55]
1.3 [1.12, 1.51]
4.03 [3.47, 4.68]
1.53 [1.23, 2.59]
4.74 [3.81, 8.03]
1.51 [1.16, 1.92]
4.68 [3.6, 5.95]
<.001
Ratio of change in creatinine from baseline 1.37 [1.28, 1.56] 0.92 [0.82, 1.03] 1.38 [1.31, 1.63] 0.91 [0.75, 0.99] <.001
IRIS stage at 365 days 1 – 6 (4.8%) – –
2 12 (14.5%) 95 (76.6%) 1 (6.3%) 26 (86.7%)
3 51 (61.4%) 23 (18.5%) 12 (75%) 4 (13.3%)
4 20 (24.1%) – 3 (18.7%) –
Note: Descriptive statistics; median [25th percentile, 75th percentile].
Abbreviations: IRIS, International Renal Interest Society; n, number; PCV, packed cell volume; PUC, positive urine culture; SB, subclinical bacteriuria; True
UTI, cats with urinary tract infection with clinical signs.
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of true UTI.7 In our study, it was not possible to assess the potential
impact of nontreatment of subclinical bacteriuria on either progression
of CKD or survival because all cats received antimicrobial treatment,
and further work is required to explore this concern. The duration of
antimicrobial treatment in our retrospective study also was substan-
tially longer than currently recommended International Society for
Companion Animal Infectious Diseases (ISCAID) guidelines.5 Our retro-
spective study includes data collected before June 2015; after this time
the clinic protocols were altered and shorter courses of antibiotics were
prescribed. Current ISCAID guidelines recommend that sporadic UTIs
be treated only for 3 to 5 days, and that subclinical bacteriuria not be
treated. However, these recommendations are based on expert opinion
and extrapolation from human medicine, and the impact of these
changes on survival and progression of renal disease warrants further
study.5
The cats in our study had regular veterinary visits and urinalyses
performed, which allowed prompt detection and treatment of PUC.
This could explain the lack of significant difference in either progres-
sion or survival, because rapid identification and treatment may have
decreased the risk of ascending infection and pyelonephritis. The PUC
cats also had significantly more veterinary visits and urinalyses per-
formed than did the no-PUC cats, because the identification of a PUC
would have prompted frequent reexaminations and repeat urinalyses.
The PUC cats in our study thus were closely monitored, which may
not reflect the situation in the general cat population where cats with
CKD could have occult, untreated PUC for prolonged periods of time,
potentially predisposing them to development of pyelonephritis and
deteriorating renal function.
The prevalence of PUC in our study was 18%, which is comparable,3
or slightly less,6 than previously reported in azotemic cats. Of the cats
that ever had a PUC, 40% subsequently would have at least 1 repeated
episode of PUC despite treatment. In our study, urine culture was not
performed routinely in all cats from which urine samples were obtained.
For financial reasons, urine cultures were only performed in those cats in
which historical clinical signs, sediment examination findings or both
suggested the possibility of bacteriuria or clinical UTI. It is therefore possi-
ble that the lower prevalence in our study is a consequence of failure to
identify bacteriuria. However, previous information (unpublished data)
indicates that the sensitivity and specificity for identifying bacteriuria in
our research clinic is 100% and 98% respectively (n = 135 samples, preva-
lence of PUC 10.4%, unpublished data), and a previous study determined
that urine cultures are unlikely to be positive in the absence of an active
urine sediment.18
In 8 cats, persistently PUC were identified during follow-up
despite antimicrobial treatment prescribed on the basis of sensitivity
data, and these cats were assigned to the 1 PUC group. Two of these
cats had persistent Enterococcus bacteriuria, and the remaining 6 cats
had persistent E. coli bacteriuria. Identification of 1 vs multiple PUC in
our study was dependent on the presence of a negative urine culture
after antimicrobial treatment. Where this was not achieved it was dif-
ficult to be certain whether serial PUC reflected persistence or rein-
fection. However, to mitigate for this uncertainty, progression and
survival analyses were performed both with and without these 8 cats.
Results of the progression and survival analyses did not change when
these cats were excluded. However, given concern in recent years
about the colonization of bladder wall urothelium,19 it also remains
possible that despite negative cultures in between PUC, some of the
repeated PUC could reflect persistence and relapse rather than reinfection.
Of the 159 documented PUC in our study population, only
22 PUC (13.8%) were accompanied by lower urinary tract signs. In a
previous study of cats with CKD, only 2 out of 25 cats with PUC were
reported to have clinical signs of lower urinary tract disease.6 This
finding emphasizes the frequency of subclinical bacteriuria in cats
with CKD, which occurs more often than true UTI in these patients.
Evaluating all PUC, the most frequently isolated bacteria in our study
were E. coli (75.5%) and E. faecalis (13.8%), consistent with previous
findings.6,20 In our study, E. coli (77.3%) and E. faecalis (18.2%) were
the most frequently isolated organisms in episodes of true UTI. These
organisms also have been shown to be the most common in a previ-
ous study of cats with lower urinary tract signs, although other organ-
isms also were identified, including Staphylococcus felis (19.8% of
isolates), such that the overall prevalence of E. coli (37.3%) and
E. faecalis (27%) was lower than in our study. It is possible that S. felis
was overlooked by the microbiology laboratory used for our study
because these organisms may be present in relatively low numbers
and may be inadvertently dismissed as contaminents.20 Female cats
more frequently were affected by PUC than male cats, as expected
from earlier studies.21-23 Our study also identified decreased PCV and
increased plasma phosphorus concentration as associated with progres-
sive CKD, as previously described.13 Additionally, Cox proportional haz-
ards analysis showed that PCV and plasma concentrations of phosphorus
and creatinine were associated with survival time, as determined in previ-
ous studies.10-12
Our study had several limitations, particularly given its retrospec-
tive nature and reliance on owner accounts to determine whether PUC
was associated with lower urinary tract signs or not, and also that rele-
vant details in relation to lower urinary tract signs had been entered
into the clinical records. For the purposes of our study, it was assumed
that when no clinical signs of lower urinary tract disease were reported
in the clinical records, the PUC episode was subclinical and not a true
UTI, and it is possible that this approach resulted in misclassification of
some PUC episodes. A standardized historical information form with
standardized questions is used in the clinic, but it remains possible that
some cats assigned to the subclinical category could have had clinical
signs that were missed either by the owner or by inadequate clinical
annotation. Another important limitation of our study is the inability to
fully exclude the possibility of chronic pyelonephritis in the PUC cats.
Abdominal imaging and pyelocentesis were not performed as part of
the standard monitoring of cats attending these longitudinal monitoring
clinics, and no attempt was made to review serial short-term changes in
plasma creatinine concentration associated with episodes of PUC.
Therefore, conclusions cannot be drawn regarding whether the pres-
ence of chronic pyelonephritis could have resulted in decreased survival
time or progression of CKD in this population of cats. A further limita-
tion is that in order to be classified as having true UTI, PUC cats had to
exhibit clinical signs of lower urinary tract disease. We elected not to
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include cats with nonspecific signs that could have been associated
with upper urinary tract infection (eg, vomiting, inappetence) in the true
UTI group, because without the aid of further diagnostic tests it was
not possible to determine whether these cats had clinical signs of
chronic pyelonephritis, CKD or other disease. It is therefore possible
that some of the cats classified as having subclinical bacteriuria could
have been misclassified.
Although the cats in our study underwent standardized monitor-
ing, timely reexaminations were dependent on owner compliance.
This resulted in occasionally missing clinical data and the inability to
determine whether all deaths were related to CKD or another cause.
Some cats were lost to follow-up during the study period and there-
fore were censored in the survival analysis. Also, a limited number of
cats was available in the multiple PUC group (n = 37), which could
have decreased the chance of significant findings in this group.
In conclusion, we found that the presence of ≥1 PUC had no
effect on survival or progression of CKD during a 12-month period in
a population of azotemic cats undergoing standardized monitoring
and receiving antimicrobial treatment for PUC. Whether the PUC was
subclinical or associated with clinical signs of lower urinary tract dis-
ease had no impact on the rate of CKD progression in these cats.
However, these findings must be viewed in light of the limitations of
the study, including the lack of abdominal imaging and inability to fully
exclude the presence of chronic pyelonephritis in the PUC cats. The
fact that most cats had International Renal Interest Society (IRIS) stage
2 CKD at the time of enrollment and that possible changes in muscle
mass that could have affected plasma creatinine concentrations were
not incorporated into the progression analysis. Current recommenda-
tions are not to treat episodes of subclinical bacteriuria with
antibiotics,5 but this recommendation is based on a desire to decrease
unnecessary antibiotic use rather than any specific evidence.24 Fur-
ther investigations are warranted to explore the clinical relevance of
untreated subclinical bacteriuria in cats with CKD.
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